Abstract: A method and composition for potentiating the effects of neuroleptic drugs by administering to a human having a disorder normally treatable with a neuroleptic drug, a neuroleptic drug in combination with a potentiating amount of an amino acid of the formula ##SPC1##Where R is fluorine, chlorine, bromine or trifluoromethyl and their salts.

Abstract: Compositions especially useful for treating inflammation topically in animals comprising an active compound having the structural formula ##SPC1##Where R is H, lower alkyl, lower alkoxy, halogen, CF.sub.3, NO.sub.2, OH, CN, COOR.sub.1, ##EQU1## NHCOR.sub.1 or NR.sub.1 R.sub.2 where R.sub.1 and R.sub.2 are each selected from the group consisting of H and lower alkyl, R, R.sub.1 and R.sub.2 being the same or different, and n is 0-5; and where X is an alkyl or alkenyl chain having 2-8 carbon atoms, one of which carbon atoms may be in the form of a carbonyl group, and Y is hydrogen, alkyl, aryl, aralkyl or aryl and aralkyl substituted with one or more R; and pharmaceutically acceptable salts thereof, together with a pharmaceutical carrier containing an effective amount of an active radical having the structural formula ##SPC2##Where n is 1-4 and A is H or ##SPC3##And Z is H or --CH=NOH or --CONHOH and one and only one Z in a heterocyclic ring is H.

Abstract: A method for assaying prostaglandins of the F.sub..alpha. series by reacting a compound of this series with a compound having the formula R--B(OH).sub.2 wherein R is a radical containing a fluorescent or radioactive label, isolating the reaction product and measuring the amount of fluorescence or radioactivity of the reaction product.

Abstract: A method for assaying prostaglandins of the E and F series comprising the sequential steps of reducing the keto groups in a sample containing the prostaglandins to hydroxy groups, selectively oxidizing the prostaglandin 15-OH groups to keto groups, reducing the keto groups to hydroxy groups by means of a radioactive labeled chemical reducing agent, isolating radioactive labeled prostaglandins and measuring the amount of radioactivity of the isolated radioactive labeled prostaglandins.

Abstract: A method for assaying prostaglandins of the E series by reacting a compound of this series with NaB.sup.3 H.sub.4, isolating the tritiated prostaglandin and measuring its radioactivity.

Abstract: There is disclosed a method for topically administering griseofulvin to a human or animal in a manner such that a high degree of epidermal, especially stratum corneum, retention of griseofulvin is attained by contacting the skin of a human or animal with an effective amount of a therapeutic composition containing griseofulvin and 2-pyrrolidone or an N-lower alkyl-2-pyrrolidone.